Alcon introduces NGENUITY® 3D Visualization System with DATAFUSION™ to simplify, customize vitreoretinal surgery

VANCOUVER, Canada, July 20, 2018 /PRNewswire/ -- Alcon, the global leader in eye care and a division of Novartis, launches the new NGENUITY 3D Visualization System with DATAFUSION at the 2018 American Society of Retina Specialists (ASRS) annual meeting. The high-definition screen of the NGENUITY system will continue to provide retinal surgeons unprecedented 3D visualization of the back of the eye with greater depth and detail during surgery than traditional microscopes. With the addition of the DATAFUSION software, NGENUITY now also offers integration with the CONSTELLATION Vision System, the leading technology platform for vitreoretinal surgery.

"At Alcon, we are always looking for ways to bring forth additional functionality and integrations that help surgeons have the most optimal and immersive surgical experience possible," said Sergio Duplan, Region President, North America, Alcon. "The NGENUITY 3D Visualization System with DATAFUSION represents a new age of integration in the surgical retina field. We are combining two of our game-changing systems to streamline the customer experience, allowing surgeons to track real-time data feedback on one screen during procedures."

The DATAFUSION software integrates the CONSTELLATION Vision System and the NGENUITY 3D Visualization System, allowing surgeons to track key data parameters in real-time, such as intraocular pressure, flow rates, infusion pressure and laser power, on one screen. Additional functionality simplifies the surgical experience allowing for customization, including the introduction of four preset imaging modes, two footswitch control options, advanced 2D or 3D video capture, and enhancement of the graphical user interface and procedure flow to provide an improved white balance process.

The viewing platform of the NGENUITY 3D Visualization System revolutionized vitreoretinal surgery when it was first launched. Compared to traditional analog microscopes, NGENUITY delivers up to 19 percent increased magnification to amplify the view for intricate tasks, up to 2.7 times extended depth of field to maintain focus across an expanded surgical space, and up to 19 percent increased depth resolution to resolve fine details when managing challenging pathologies.¹

"When you're performing hundreds of eye surgeries each year, the technology matters. I was an early adopter of the NGENUITY 3D Visualization System and am thrilled with DATAFUSION because it has really helped me streamline my surgery process," said Steve Charles, MD, Charles Retina Institute in Germantown, Tenn. "The depth of field and level of magnification it provides, as well as the integration with the CONSTELLATION Vision System, means I have all the most important information front and center so I can deliver the very best outcomes to my patients."

The NGENUITY 3D Visualization System with DATAFUSION is now available and can be experienced first-hand, along with other new product offerings from Alcon, at the ASRS Alcon booth #401 beginning Saturday, July 21, 2018.  

About Vitreoretinal Surgery

Vitreoretinal surgery is a sub-specialty of ophthalmology focused in diseases and surgery of the back of the eye including the retina and the vitreous body of the eye. The retina is a light-sensitive area that includes the macula, which is made up of light-sensitive cells that provide sharp, detailed vision. The vitreous body of the eye is a clear gel that fills the space between the retina and the lens. The retina, the macula, and the vitreous body can all be subject to various diseases and conditions that can lead to blindness or vision loss and may require the attention of a vitreoretinal surgeon.

About NGENUITY 3D Visualization System

The NGENUITY 3D Visualization System was developed in collaboration with TrueVision^® 3D Surgical, a California-based leader in digital 3D visualization and guidance for microsurgery. It consists of a 3D stereoscopic, high-definition digital video camera and workstation to provide magnified stereoscopic images of objects during micro-surgery. Additional functionality updates simplify the surgical experience allowing for customization, including the introduction of four preset imaging modes, two footswitch control options, advanced 2D or 3D video capture, and enhancement of the graphical user interface and procedure flow to provide an improved white balance process. Please refer to the User Manual for a complete list of appropriate uses, warnings and precautions.

Disclaimer

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "expect," "anticipate," "look forward," "commitment," "investigational," "launches," or similar terms, or by express or implied discussions regarding potential marketing approvals or clearances, new approved uses or labeling for the investigational or approved products or devices described in this press release, or regarding potential future revenues from such products and devices. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational, cleared or approved products and devices described in this press release will be submitted, cleared or approved for sale or for any additional uses or labeling in any market, or at any particular time. Nor can there be any guarantee that such products or devices will be widely available and/or commercially successful in the future. In particular, our expectations regarding such products and devices could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and cost pressures; our ability to obtain or maintain proprietary intellectual property protection; the particular preferences of physicians; general political and economic conditions; safety, quality or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Alcon 

Alcon is the global leader in eye care. As a division of Novartis, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our products touch the lives of more than 260 million people each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors, and there are millions more who are waiting for solutions to meet their eye care needs. Our purpose is reimagining eye care, and we do this through innovative products, partnerships with eye care professionals and programs that enhance access to quality eye care. Learn more at www.alcon.com.

Alcon is on Facebook. Like us at www.facebook.com/AlconEyeCare

About Novartis

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2017, the Group achieved net sales of USD 49.1 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 125,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. For more information, please visit http://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis
For Novartis multimedia content, please visit www.novartis.com/news/media-library
For questions about the site or required registration, please contact [email protected]

References:

1. Alcon Data on File.

Novartis Media Relations
Central media line: +41 61 324 2200
E-mail: [email protected]

Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: [email protected]

SOURCE Novartis